NRX 195183

· NuRx Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NRX 195183, covering 2008-05-12 to 2008-05-12. Get the full timeline:

Most recent: Clinical Trial Update: Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia [Phase 2]